source
- Lycia Therapeutics targets $228M IPO to fund food allergy protein degrader programsLycia Therapeutics announced plans for an initial public offering expected to raise about $228 million. The proceeds are intended to support its pipeline of protein degrader therapeutics targeting…
- SCRS unveils Eagle Insights Dashboard to benchmark clinical trial site performanceThe Society for Clinical Research Sites introduced a new data intelligence platform called the Eagle Insights Dashboard. The tool provides sponsors and contract research organizations with a compos…